WildProse -- You obviously can't read THE ANALYST'S REPORT STATES THE FOLLOWING:
- f/d approx. 53 million shares, insiders control at least 20% f/d shares
(I WOULD THINK HE IS INCLUDING OUTSTANDING WARRANTS)
- all amounts in USD unless otherwise indicated
- Based on the research and analysis below, it is my opinion that
Advectus’ Nanocure™ project for malignant brain cancer therapy
using nanotechnology has an estimated present value of $388 million,
based on US market demand only and terminal sales in 2018
(THIS MEANS THE PRESENT DAY VALUE OF AVX IS $388 MILLION
AND THAT HE EXPECTS SALES OF NANOCURE TO END IN 2018 --
WILD PROSE OBVIOUSLY IS VERY DENSE AND DOES NOT UNDERSTAND
THIS STATEMENT)
THEN THE ANALYST GOES ON TO SAY....
- At current stock price levels, AVX stock should be considered as a
reasonable, speculative buy for investors interested in high-risk
investments
- A target stock price range is inestimable given the early stage of
Advectus’ project